COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,625 Articles (22,913 medRxiv, 8,712 bioRxiv)

Most recent first Previous |  Page 1786: Articles 17851-17860  | Next

Disinfection of SARS-CoV-2 contaminated surfaces of personal items with UVC-LED disinfection boxes
Bormann, M., Alt, M., Schipper, L., van de Sand, L., Otte, M., Meister, T. L., Dittmer, U., Witzke, O., Steinmann, E., Krawczyk, A.
10.1101/2021.03.03.433725 — Posted: 2021-03-04
T-cell Repertoire Characteristics of Asymptomatic and Re-detectable Positive COVID-19 Patients
Xu, J., Shi, Y., Wang, Y., Liu, Y., Lin, D., Zhang, J., Lin, J., Hu, W., He, H., Wang, W., Fan, W., Li, L., Lan, H., Lei, C., Wang, K., Wang, D.
10.1101/2021.03.03.433579 — Posted: 2021-03-04
UBXN3B Restricts Viral Pathogenesis by Maintaining Hematopoietic Homeostasis
WANG, P., Geng, T., Yang, D., Lin, T., Harrison, A., Haynes, L., Torrance, B., Wang, B., Vella, A. T., Cheng, G., Fikrig, E., Yang, L.
10.1101/2021.03.04.433919 — Posted: 2021-03-04
A novel conformational state for SARS-CoV-2 main protease
Fornasier, E., Macchia, M. L., Giachin, G., Sosic, A., Pavan, M., Sturlese, M., Salata, C., Moro, S., Gatto, B., Bellanda, M., Battistutta, R.
10.1101/2021.03.04.433882 — Posted: 2021-03-04
Structural insights into plasticity and discovery of remdesivir metabolite GS-441524 binding in SARS-CoV-2 macrodomain
Ni, X., Schroeder, M., Olieric, V., Sharpe, M. E., Olmos, V., Proschak, E., Merk, D., Knapp, S., Chaikuad, A.
10.1101/2021.03.04.433966 — Posted: 2021-03-04
Inhibiting SARS-CoV-2 infection in vitro by suppressing its receptor, angiotensin-converting enzyme 2, via aryl-hydrocarbon receptor signal
Tanimoto, K., Hirota, K., Fukazawa, T., Matsuo, Y., Nomura, T., Tanuza, N., Hirohashi, N., Bono, H., Sakakuchi, T.
10.1101/2021.03.04.433658 — Posted: 2021-03-04
Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation
Su, X., Ma, W., Cheng, B., Wang, Q., Guo, Z., Zhou, D., Tang, X.
10.1101/2021.03.04.433849 — Posted: 2021-03-04
SARS-CoV-2 viability in time on experimental surfaces
Nikiforova, M., Siniavin, A., Shidlovskaya, E., Kuznetsova, N., Gushchin, V.
10.1101/2021.03.04.433846 — Posted: 2021-03-04
The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Ndeupen, S., Qin, Z., Jacobsen, S., Gibb, M., Estanbouli, H., Bouteau, A., Cardenas, J., Uthra, B., Wang, Y., Gu, J., Igyarto, B. Z.
10.1101/2021.03.04.430128 — Posted: 2021-03-04 Discussion: Onsite
SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
Vogel, M., Chang, X., Sousa Augusto, G., Mohsen, M. O., Speiser, D. E., Bachmann, M. F.
10.1101/2021.03.04.433887 — Posted: 2021-03-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).